1. Treatment of Metastatic Pancreatic Cancer with a Combination of Gemcitabine and 5-Fluorouracil: A Single Center Phase II Study
- Author
-
Murat Arslan, Ender Kurt, Guzin Gonullu, Mutlu Demiray, Ozkan Kanat, Osman Manavoglu, Turkkan Evrensel, Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Bilim Dalı., Kanat, Özkan, Evrensel, Türkkan, Kurt, Ender, Demiray, Mutlu, Gönüllü, Güzin, Arslan, Murat, Manavoğlu, Osman, AAJ-1027-2021, and M-8060-2019
- Subjects
Male ,Oncology ,Cancer Research ,Phases of clinical research ,Single Center ,Deoxycytidine ,Gastroenterology ,Trial ,Metastasis ,030218 nuclear medicine & medical imaging ,0302 clinical medicine ,Bolus (medicine) ,Antineoplastic Combined Chemotherapy Protocols ,5-fluorouracil ,Pancreas cancer ,Survival time ,Drug tolerability ,Analgesics ,Leukopenia ,Anemia ,Pancreas Adenocarcinoma ,Gemcitabine ,Pancreatic Neoplasms ,General Medicine ,Middle Aged ,Serotonin 3 antagonist ,Clinical trial ,Treatment Outcome ,Fluorouracil ,030220 oncology & carcinogenesis ,Injections, Intravenous ,Disease Progression ,Female ,medicine.symptom ,Human ,medicine.drug ,Adult ,Diarrhea ,Antimetabolites, Antineoplastic ,medicine.medical_specialty ,Clinical article ,Drug response ,Adenocarcinoma ,Drug Administration Schedule ,Article ,Drug toxicity ,03 medical and health sciences ,Mucosa inflammation ,Internal medicine ,medicine ,Mucositis ,Humans ,Chemotherapy ,High-dose leucovorin ,Phase 2 clinical trial ,Aged ,business.industry ,Body Weight ,Pancreatic cancer ,medicine.disease ,Survival Analysis ,Thrombocytopenia ,Cancer survival ,Cancer combination chemotherapy ,Drug effect ,Drug efficacy ,Regimen ,Tract cancer ,Antiemetic agent ,business - Abstract
AimTo determine the activity and toxicity of a combination of weekly gemcitabine and 5-fluorouracil bolus intravenously in patients with metastatic pancreatic cancer.Patients and methodsTwenty-one patients with previously untreated metastatic pancreatic cancer were included in this phase II study. The schedule was gemcitabine (1000 mg/m2iv) and 5-fluorouracil (500 mg/m2bolus iv) weekly for 3 weeks every month.ResultsFour patients (19%) achieved a partial response and three stable disease. A clinical benefit was obtained in 7 patients (33%). Median survival for all the patients was 6 months. The treatment was well tolerated and toxicity was mild. WHO grade 3 leukopenia occurred in 2 (9.5%) patients, grade 3 anemia in 4 (19%) patients, grade 3-4 thrombocytopenia in 4 (19%) patients, grade 1 diarrhea in 1 (4.7%) patient and grade 1 mucositis in 3 (14.2%) patients.ConclusionThe weekly administration of gemcitabine combined with 5-fluorouracil bolus iv is an active and well-tolerated regimen in metastatic pancreatic cancer. However, its efficacy is relatively limited.
- Published
- 2004
- Full Text
- View/download PDF